Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-20 | 2024-06 | 0 | N/A | N/A | N/A |
2024-07-01 | 2024-03 | 0 | N/A | N/A | N/A |
2023-02-28 | 2022-12 | -0.19 | N/A | N/A | N/A |
2022-11-08 | 2022-09 | -0.25 | -0.2 | 0.05 | 20.00% |
2022-08-15 | 2022-06 | -0.23 | -0.31 | -0.08 | -34.78% |
2022-05-05 | 2022-03 | 0 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-02 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-03-25 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-09 | HC Wainwright & Co. | Upgrade | Buy | |
2021-01-21 | Alliance Global Partners | Upgrade | Buy | |
2020-07-31 | HC Wainwright & Co. | Upgrade | Buy | |
2020-05-26 | Dawson James | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-09-12 | ABG MANAGEMENT, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2021-03-15 | ASGHAR NAJJAM | Chief Financial Officer | 56.97K | Stock Award(Grant) |
2018-01-23 | ASIA PACIFIC MEDTECH BVI, LTD. | Beneficial Owner of more than 10% of a Class of Security | 8.62M | Sale |
2020-12-15 | FOLLOWWILL DORMAN | Director | 2.13K | Sale |
2021-12-26 | JANDA KIM D | Director | 3.00K | Sale |
2022-12-20 | JI HENRY H | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | State Street Corporation | 50.64M | 15.56M | 10.73% |
2022-12-30 | Blackrock Inc. | 39.42M | 12.11M | 8.35% |
2022-12-30 | Vanguard Group, Inc. (The) | 29.54M | 9.08M | 6.26% |
2022-12-30 | Geode Capital Management, LLC | 8.91M | 2.74M | 1.89% |
2022-12-30 | B. Riley Financial, Inc. | 5.22M | 1.60M | 1.11% |
2022-12-30 | B. Riley Securities, Inc. | 5.22M | 1.60M | 1.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 40.89M | 12.56M | 8.66% |
2022-09-29 | Vanguard Total Stock Market Index Fund | 12.84M | 3.95M | 2.72% |
2022-12-30 | iShares Russell 2000 ETF | 10.36M | 3.18M | 2.20% |
2022-09-29 | Vanguard Extended Market Index Fund | 5.51M | 1.69M | 1.17% |
2022-12-30 | Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh | 4.27M | 1.31M | 0.91% |
2022-12-30 | iShares Russell 2000 Value ETF | 4.11M | 1.26M | 0.87% |
Split | Date |
---|---|
0.04 : 1 | 2013-08-01 |
0.1 : 1 | 2008-10-07 |
-
My family left me for losing all of our money. $SRNE
-
-
-
-
-
$SRNE complete piece of shit and trash.
-
I am long and I feel like my family is suffering
Let’s go already -
-
Anybody else just at a standstill with $SRNE? The only thing holding me here is my stubbornness.
-
How does this stock Still have a 1.8 billion dollar market cap? They have nothing but empty promises. Yes the oncology pipeline looks great on paper. So does their COVID pipeline. They just move onto whatever the next. And STILL, they have not been able to produce a single product. Use logic snd reason investors, not hope and change.
-
Logic says if you truly had an Ab cure that is 100% effective, you don’t need to waste your time on a COVID test or even a vaccine. You would spend all your resources on that one cure you have. But if you don’t, then you start to talk about testing and vaccine and how we have over 100 PhD working on a vaccine. Use the smell test investors. I’m sick of these types of companies. That is why I post. No other reason. We spend our hard earned money just to be scammed by companies and people like this. Unethical.
-
-
SRNE is a Chinese company thats why Trump didn’t add them to Operational Warp Speed. Its obvious!
-
SRNE is a Chinese company thats why it was not selected for Operation Warp Speed.
-
-
-
-
-
-
The temptation to buy more